证券代码：605033 证券简称：美邦股份 公告编号：2025-056 陕西美邦药业集团股份有限公司 2025年前三季度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 通过分配方案的股东会届次和日期 本次利润分配方案经陕西美邦药业集团股份有限公司（以下简称"公司"）2025 年 5 月 16 日的2024年年度股东会授权，2025 年 10 月 28 日召开的第三届董事会第九次会议审议通 过。 二、 分配方案 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任公司上海分 公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 每股分配比例 A 股每股现金红利0.05元 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/12/9 | － | 2025/12/10 | 2025/12/10 | 差异化分红送转： 否 3. 分配方案： ...

Core Viewpoint - The company announced the redemption of a financial product, indicating effective cash management and the ability to generate returns on idle funds [1] Group 1: Financial Management - The company redeemed a financial product from CITIC Bank, recovering a principal amount of 15 million yuan [1] - The company received an investment return of 107,400 yuan from the financial product [1] - The redeemed funds have been transferred to a dedicated account for raised funds, ensuring compliance with investment project progress [1] Group 2: Operational Impact - The cash management redemption will not affect the progress of investment projects funded by raised capital [1] - The company plans to continue cash management using idle raised funds, indicating a proactive approach to financial resource utilization [1]

Core Viewpoint - Meibang Co., Ltd. has made significant progress in the Indonesian market by obtaining five drug registration certificates, enhancing its presence in Southeast Asia [1] Group 1 - Meibang Co., Ltd. has received approval for five original drug registration certificates in Indonesia [1] - The company is actively registering multiple products in Indonesia, with expectations for more approvals in the next two years [1]

Core Viewpoint - The growth regulator, brassinosteroid, is gaining traction in the agricultural sector due to national green pesticide policies, with its market size expected to reach 1.5 billion yuan in 2024 and exceed 2 billion yuan by 2030 [1][10]. Industry Overview - Brassinosteroid, with the chemical formula C28H48O6, is a new type of green and environmentally friendly plant growth regulator, widely present in plants and known for its high biological activity [3]. - It promotes the growth of various crops, improves quality, and increases yield, making it popular among farmers, especially in the production of economic crops like fruits, vegetables, and flowers, as well as major crops like rice, wheat, and corn [1][10]. Industry Policies - The market for brassinosteroid is gaining attention due to its high efficiency, broad spectrum, and safety features, which align with the increasing focus on food security and green agriculture policies [5][6]. - Recent policies, such as the implementation of the "14th Five-Year Plan" for agricultural green development, emphasize the safe and efficient application of plant growth regulators [12]. Industry Chain - The brassinosteroid industry chain includes upstream components like steroid compounds and solvents, midstream production, and downstream applications in agriculture, horticulture, and forestry [7]. - The total sown area of crops in China is projected to grow from 165.9 million hectares in 2018 to 173 million hectares in 2024, with a compound annual growth rate of 0.7%, driving the demand for pesticides, including brassinosteroid [7]. Current Industry Status - The pesticide industry in China has developed a complete industrial system, becoming the largest pesticide producer globally. The production of chemical pesticide raw materials is expected to increase significantly due to supportive national policies and product structure optimization [8][9]. - In 2024, the production of chemical pesticide raw materials is projected to reach 3.675 million tons, a year-on-year increase of 37.6% [9]. Competitive Landscape - The brassinosteroid market in China is becoming increasingly competitive, with a growing number of companies entering the sector, including Meibang Co., Ltd. and *ST Huifeng [2][10]. - Companies like Yunnan Yunda Technology Agricultural Chemical Co., Ltd. are focusing on research and development of brassinosteroid products, contributing to the industry's growth [11]. Industry Development Trends - The market for brassinosteroid is expected to expand due to increased support for green agriculture and rising consumer demands for high-quality agricultural products [12]. - The industry is witnessing a trend towards consolidation, with smaller companies facing challenges, while those with advantages in technology and market promotion are likely to thrive [13]. - The development of long-lasting brassinosteroid products is becoming a key focus, supported by advancements in technologies that enhance the effectiveness and duration of these products [14].

Group 1 - The core point of the news is that Meibang Co., Ltd. (605033.SH) reported its Q3 2025 results, revealing a total of 16.0152 million A-shares held by four institutional investors, accounting for 11.85% of the total share capital, which is a decrease of 1.41 percentage points from the previous quarter [1] - Institutional investors include Lianyungang Tongmei Enterprise Management Co., Ltd., Lianyungang Meifu Enterprise Management Consulting Partnership (Limited Partnership), Lianyungang Meiping Enterprise Management Consulting Partnership (Limited Partnership), and UBS AG [1] - Three public funds were disclosed this period, including Nuoan Innovation-Driven Mixed A, Jiaoyin Trend Mixed A, and Xinhua Xin Technology 3-Month Rolling Flexible Allocation Mixed A, which were not reported in the previous quarter [1] Group 2 - One new foreign institution, UBS AG, was disclosed this period, while BARCLAYS BANK PLC was not reported in the current quarter [1]

Group 1 - The core point of the article is that Meibang Co., Ltd. announced the convening of its third board meeting on October 28, 2025, to discuss the profit distribution plan for the first three quarters of 2025 [1] - For the year 2024, the revenue composition of Meibang Co., Ltd. is reported to be 99.49% from pesticides and 0.51% from other businesses [1] Group 2 - The A-share market has surpassed 4000 points, marking a significant resurgence after a decade of stagnation, with technology leading the market's transformation into a "slow bull" new pattern [1]

Core Insights - Meibang Co., Ltd. (605033.SH) reported a revenue of 609 million yuan for the first three quarters of 2025, reflecting a year-on-year decline of 2.23% [1] - The company's net profit attributable to shareholders was 36.2 million yuan, down 16.36% year-on-year [1] - The non-recurring net profit stood at 29.62 million yuan, showing a decrease of 5.57% compared to the previous year [1] - Basic earnings per share were reported at 0.27 yuan [1]

Core Viewpoint - Meibang Co., Ltd. reported a decline in revenue and net profit for the first three quarters of 2025, indicating potential challenges in its financial performance [1][2]. Financial Performance - The company's revenue for the first three quarters was 609 million yuan, a year-on-year decrease of 2.23% [1]. - The net profit attributable to shareholders was 36.1961 million yuan, down 16.36% year-on-year [1]. - The net profit after deducting non-recurring items was 29.6248 million yuan, a decline of 5.57% year-on-year [1]. - Basic earnings per share stood at 0.27 yuan [1]. Profitability Metrics - The gross profit margin for the first three quarters was 33.40%, an increase of 2.65 percentage points year-on-year [2]. - The net profit margin was 5.94%, a decrease of 1.00 percentage point compared to the same period last year [2]. - In Q3 2025, the gross profit margin was 35.09%, up 2.49 percentage points year-on-year and 3.05 percentage points quarter-on-quarter [2]. - The net profit margin for Q3 was 0.05%, an increase of 3.72 percentage points year-on-year but a decrease of 3.11 percentage points quarter-on-quarter [2]. Expense Analysis - Total operating expenses for the period were 169 million yuan, an increase of 25.2941 million yuan year-on-year [2]. - The expense ratio was 27.77%, up 4.68 percentage points from the previous year [2]. - Sales expenses increased by 21.96%, while management expenses decreased by 1.01% [2]. - R&D expenses rose by 20.61%, and financial expenses increased by 41.94% [2]. Shareholder Information - As of the end of Q3 2025, the total number of shareholders was 12,100, a decrease of 1,122 from the end of the previous half-year, representing an 8.48% decline [2]. - The average market value of shares held per shareholder increased from 202,600 yuan to 248,200 yuan, a growth of 22.50% [2]. Company Overview - Meibang Co., Ltd. is located in Xi'an, Shaanxi Province, and was established on August 5, 1998, with its listing date on September 16, 2021 [3]. - The company's main business includes the research, production, and sales of pesticide formulations, as well as agricultural technology promotion services [3]. - The revenue composition is as follows: fungicides 51.82%, insecticides 35.05%, and others 12.62% [3].

主要产品 2025 年 1 至 9 月产 量（吨） 2025 年 1 至 9 月销 量（吨） 2025 年 1 至 9 月销 售金额（万元） 杀菌剂 3,867.90 3,848.78 33,106.82 杀虫剂 2,013.69 2,316.43 19,152.57 其他 1,491.24 1,396.50 8,355.65 一、主要产品的产量、销量及收入实现情况（不含税） 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 根据上海证券交易所《上海证券交易所上市公司自律监管指引第3号行业信 息披露：第十三号——化工》的相关要求，陕西美邦药业集团股份有限公司（以 下简称"公司"）现将2025年第三季度主要经营数据披露如下： 二、主要产品的价格变动情况（不含税） | 主要产品 | 年 2025 1 9 均售价（元/吨） | 至 | 月平 | 年 2024 1 均售价（元/吨） | 至 9 | 月平 | 变动比率（%） | | | --- | --- | --- | --- | --- | --- | --- | --- | ...

证券代码：605033 证券简称：美邦股份 公告编号：2025-053 陕西美邦药业集团股份有限公司 第三届董事会第九次会议决议公告 同意公司 2025 年第三季度报告。 赞成票：9 票；反对票：0 票；弃权票：0 票。 本议案相关内容详见上海证券交易所网站 www.sse.com.cn《陕西美邦药业集 团股份有限公司 2025 年第三季度报告》。 （二）审议并通过《关于公司 2025 年前三季度利润分配预案的议案》 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、董事会会议召开情况 陕西美邦药业集团股份有限公司（以下简称"公司"）第三届董事会第九次 会议于 2025 年 10 月 28 日在陕西省西安市未央区草滩三路 588 号公司三楼会议 室召开。本次会议通知于 2025 年 10 月 23 日以电话或书面通知方式发出，会议 采用现场和视频通讯方式召开，会议应到董事 9 人，实到董事 9 人。会议由董事 长张少武先生主持，会议的召集、召开符合《中华人民共和国公司法》及公司章 程的有关规定。经董事认真审议，通过了以 ...